Successful therapy of experimental, orthotopic renal cell carcinoma with two different types of AXL-inhibiting agents

Abstract number: P0555

Tony J. Chen
Tony.Chen@uib.no
Conflict of Interest Disclosure

Parts of this study were done in collaboration with BerGenBio that also provided AXL inhibitors.
• AXL receptor, a transmembrane tyrosine kinase (RTK).

• ↑AXL: aggressive and resistant cancer.


• So; AXL is a potential target in RCC!
The aim of the study is to investigate the role of AXL-inhibitors Bemcentinib and Tilvestamab ± tyrosine kinase inhibitor Sunitinib in orthotopic RCC mice model.
786-0 Luc-cells injected in kidney capsule in 8-week old athymic nude mice

8 weeks of tumor growth

Control (n=6)  
Control IgG (n=6)  
Bemcentinib (n=6)  
Tilvestamab (n=7)  
Sunitinib (n=7)  
Bemcentinib + Sunitinib (n=7)  
Tilvestamab + Sunitinib (n=7)

Bioluminescence signals were imaged (IVIS Lumina) at week 11 and 13 after start of experiment
Results

**p < 0.002
A) Tilvestamab prevents Gas6-induced Axl phosphorylation in 786-O cells.

B) Bemcentinib prevents Gas6-induced Axl phosphorylation in 786-O cells.

Data provided by BergenBio

**** p < 0.0001
• Axl-inhibitors effectively reduce tumor size in orthotopic model.

• Both bemcentinib and tilvestamab effectively prevent GAS6 induced pAXL in 786-0 cell line.
Axl-inhibition represents a promising strategy in treatment of RCC.
Thanks for your attention